Lung (includes NSCLC, SCLC, Mesothelioma)

Cancer Drug Company Tesaro Shares Rise 39% Following Report That It Will Explore Sale

(CNBC) Nov 16, 2018 - Tesaro shares soared 39 percent Friday upon a Bloomberg report that the pharmaceutical company will explore the opportunity of a sale.

read article

AstraZeneca Provides Update on the Phase III MYSTIC Trial of Imfinzi and Tremelimumab in Stage IV Non-Small Cell Lung Cancer

(AstraZeneca) Nov 16, 2018 - AstraZeneca and MedImmune, its global biologics research and development arm, today announced final overall survival (OS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinzi and tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) platinum-based chemotherapy in previously-untreated patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). In the primary analysis population of patients, whose tumours express PD-L1 on 25% or more of their cancer cells as determined by the VENTANA PD-L1 (SP263) Assay, Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab did not meet the primary endpoints of improving OS compared to SoC chemotherapy. While the OS result did not meet statistical significance, a hazard ratio (HR) of 0.76 (97.54% CI 0.564-1.019; nominal p=0.036) was observed with Imfinzi monotherapy. The combination therapy had an HR of 0.85 (98.77% CI 0.611-1.173; nominal p=0.202); the data support further analysis in exploratory subgroups.

read corporate press release

Key AstraZeneca Lung Cancer Treatment Misses Study Goal

(Reuters) Nov 16, 2018 - AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares. The study, known as “Mystic”, was among the industry’s most anticipated clinical experiments and was viewed as central to proving the value of the group’s new drug pipeline and its future as an independent company, after it spurned a $118 billion takeover attempt by Pfizer in 2014.

read article

Lung Cancer Has A Sweet Tooth: Sugar Delivery Fuels Early Tumor Growth

(Forbes) Nov 15, 2018 - Researchers at UCLA have discovered that early stage NSCLC tumors, and even pre-cancerous lesions, give themselves away by producing unusually high levels of a molecule called SGLT2 (Sodium Glucose Transporter 2).

read article

Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers

(ALCF) Nov 14, 2018 - The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living with epidermal growth factor receptor (EGFR) positive lung cancer develop resistance to treatment over time, or do not respond at all.

read press release

Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

(MarketWatch) Nov 16, 2018 - Hutchison China MediTech Limited today announces the outcome of FALUCA, its Phase III trial of fruquintinib in advanced non-small cell lung cancer (“NSCLC”) patients in China who have failed two lines of systemic chemotherapy. The trial did not meet the primary endpoint to demonstrate a statistically significant increase in overall survival (“OS”) compared to placebo.

read article

Combination Of Two Immunotherapies Shows Activity In Non-small Cell Lung Cancer Patients

(ECCO) Nov 15, 2018 - A combination of two drugs, which prompt the body’s immune system to identify and kill cancer cells, is a safe treatment for patients with advanced non-small cell lung cancer and has shown some signs of efficacy. Results from a phase I/II clinical trial in 25 patients, presented at the 30th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Thursday), identified the maximum tolerated doses at which NIR178 (PBF-509) and spartalizumab (PDR001) could be given to patients whose disease had either failed to respond or stopped responding to previous treatments. The disease shrank or disappeared in two patients and it remained stable, without progressing, in 14 patients.

read press release

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

(Boehringer Ingelheim) Nov 15, 2018 - Boehringer Ingelheim and Epizyme, Inc. today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer. Specifically, these targets are enzymes within the helicase and histone acetyltransferase (HAT) families that when dysregulated have been linked to the development of cancers that currently lack therapeutic options.

read corporate press release

Boehringer Ingelheim and Epizyme Ink Collaboration Deal With $15 Million Upfront and $280 Million in Biobucks

(BioSpace) Nov 15, 2018 - Boehringer Ingelheim based in Ingelheim, Germany, and Epizyme, headquartered in Cambridge, Mass., signed a global collaboration deal to identify, develop and market cancer therapies. The deal could exceed $300 million. The focus will be on two previously unexplored epigenetic targets, both enzymes in the helicase and histone acetyltransferase (HAT) families. When these enzymes are dysregulated, they have been associated to cancer development. There are more than 100 members of the helicase gene family in the human genome. The HATs involve 18 enzymes that add acetyl groups to proteins including histones. Histones are proteins that DNA wraps around, and acetyl groups provide a regulatory function, turning genes on or off.

read article

ALA, ATS Seek Increase in Lung Cancer Screenings With New Healthcare Guide

(AJMC Managed Markets Network) Nov 12, 2018 - In an effort to increase the number of people getting screened, the American Lung Association (ALA) and the American Thoracic Society (ATS) unveiled a Lung Cancer Screening Implementation Guide during Lung Cancer Awareness Month.

read article

New Initiative Aims to 'Lock Up Lung Cancer'

(Curetoday.com) Nov 12, 2018 - Lock Up Lung Cancer is a new campaign to expose the disease as a prolific killer, according to LUNG FORCE.

read article

TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting

(TESARO) Nov 9, 2018 - Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatment; TSR-042 monotherapy demonstrated significant activity in patients with previously treated recurrent/advanced NSCLC across all PD-L1 TPS categories.

read corporate press release

Biodesix Test Predicts Response to Atezolizumab in Lung Cancer

(P&T Community) Nov 12, 2018 - Researchers present new data from blood-based proteomic test in biomarkers and immune monitoring at SITC 2018.

read article

Will Tarloxotinib Finally Break The HER2 Barrier In Lung Cancer?

(UCCC/Colorado Cancer Blogs) Nov 8, 2018 - A University of Colorado Cancer Center study presented at the 30th annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics shows the promise of an innovative new strategy against HER2-driven lung cancers (with EGFR involvement, which is also a well-known driver of lung cancer).

read article

New Data from Investigational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

(MarketWatch) Nov 9, 2018 - First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Study 111/KEYNOTE-146; new data support ongoing broad clinical program for LENVIMA and KEYTRUDA combination across multiple tumor types.

read article

Immunomedics Expands Clinical Collaboration With Astrazeneca To Include Metastatic Non-Small Cell Lung Cancer

(Immunomedics) Nov 7, 2018 - Immunomedics, Inc., a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced its current clinical collaboration with AstraZeneca and MedImmune for the development of Imfinzi® (durvalumab) and sacituzumab govitecan combination therapy has been broadened to include second-line metastatic non-small cell lung cancer (NSCLC).

read corporate press release

J&J Buys Novel Lung Cancer Drug From South Korea’s Yuhan

(pharmaphorum.com [UK]) Nov 7, 2018 - Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC).

read article

Novel Tracer Developed for Precision Targeting of Non-Small Cell Lung Cancer

(SNMMI) Nov 5, 2018 - Researchers have developed a new nuclear medicine tracer that could improve diagnosis and treatment of non–small cell lung cancer.

read press release

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

(Pfizer) Nov 2, 2018 - Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This represents the third FDA approval Pfizer has received for an oncology treatment, including two lung cancer medicines, within two months.

read corporate press release

FDA Approves Lorlatinib for Second- Or Third-Line Treatment Of ALK-Positive Metastatic NSCLC

(FDA.gov) Nov 5, 2018 - On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. Approval was based on a subgroup of 215 patients with ALK-positive metastatic NSCLC, previously treated with one or more ALK kinase inhibitors, enrolled in a non‑randomized, dose-ranging and activity-estimating, multi‑cohort, multicenter study (Study B7461001; NCT01970865). The major efficacy measures were overall response rate (ORR) and intracranial ORR, according to RECIST 1.1, as assessed by an independent central review committee.

read press release
Next Page